Abstract
Peptides regulate most physiological processes, mainly by binding to specific receptors located on the cell surface and inducing a series of signals, neurotransmissions or the release of growth factors. There has been a rapid expansion in the use of peptides as therapeutic agents after the 1960s, but a series of unfortunate side effects present in Phase I and II clinical studies combined with their low bioavailability, led to the introduction of the idea of peptidomimetics as alternative compounds that mimic the biological activity of peptides, while offering the advantages of increased bioavailability, biostability, bioefficiency, and bioselectivity. Since then new peptides with promising in vitro results, involving the monoclonal antibody expansion, as well as the newly launched research field for novel formulations for increasing peptides bioavailability, redirected the interest on the peptide market. In this report we will highlight three areas where the use of peptides has shown promising results, with products that are either currently used as drugs or included into Phase III clinical studies.
Keywords: Peptides, altered peptide ligands (APLs), cyclic peptide, hypertension, angiotensin, gonadotropin releasing Hormone (GnRH), multiple sclerosis (MS), immunotherapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Peptides as Therapeutic Agents or Drug Leads for Autoimmune, Hormone Dependent and Cardiovascular Diseases
Volume: 7 Issue: 4
Author(s): Efthimia Mantzourani, Despoina Laimou, Minos Timotheos Matsoukas and Theodore Tselios
Affiliation:
Keywords: Peptides, altered peptide ligands (APLs), cyclic peptide, hypertension, angiotensin, gonadotropin releasing Hormone (GnRH), multiple sclerosis (MS), immunotherapy
Abstract: Peptides regulate most physiological processes, mainly by binding to specific receptors located on the cell surface and inducing a series of signals, neurotransmissions or the release of growth factors. There has been a rapid expansion in the use of peptides as therapeutic agents after the 1960s, but a series of unfortunate side effects present in Phase I and II clinical studies combined with their low bioavailability, led to the introduction of the idea of peptidomimetics as alternative compounds that mimic the biological activity of peptides, while offering the advantages of increased bioavailability, biostability, bioefficiency, and bioselectivity. Since then new peptides with promising in vitro results, involving the monoclonal antibody expansion, as well as the newly launched research field for novel formulations for increasing peptides bioavailability, redirected the interest on the peptide market. In this report we will highlight three areas where the use of peptides has shown promising results, with products that are either currently used as drugs or included into Phase III clinical studies.
Export Options
About this article
Cite this article as:
Mantzourani Efthimia, Laimou Despoina, Matsoukas Timotheos Minos and Tselios Theodore, Peptides as Therapeutic Agents or Drug Leads for Autoimmune, Hormone Dependent and Cardiovascular Diseases, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7 (4) . https://dx.doi.org/10.2174/187152308786847799
DOI https://dx.doi.org/10.2174/187152308786847799 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) The Androgen Receptor as Putative Therapeutic Target in Hormone-Refractory Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy
Current Radiopharmaceuticals Cancer Therapeutics: Emerging Targets and Trends
Current Cancer Therapy Reviews Editorial {Hot topic: QSPR Models for Computer-Aided Drug Design in Microbiology, Parasitology, and Pharmacology (Guest Editor: Humberto Gonzalez-Diaz)]
Current Computer-Aided Drug Design Treatment of Atopic Dermatitis: Current Status and Future Prospects
Current Drug Therapy Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Current Cancer Drug Targets T Cell Redirecting Therapies for Cancer Treatment
Current Cancer Drug Targets Testosterone as Potential Effective Therapy in Treatment of Obesity in Men with Testosterone Deficiency: A Review
Current Diabetes Reviews Current and Emerging Strategies in Bladder Cancer
Anti-Cancer Agents in Medicinal Chemistry Suppression of Cancer Invasiveness by Dietary Compounds
Mini-Reviews in Medicinal Chemistry Application of MALDI/SELDI Mass Spectrometry to Cancer Biomarker Discovery and Validation
Current Proteomics Squalamine as an Example of a New Potent Antimicrobial Agents Class: A Critical Review
Current Medicinal Chemistry Gonadotropin-Releasing Hormone and GnRH Receptor: Structure, Function and Drug Development
Current Medicinal Chemistry A Functional Scaffold in Marine Alkaloid: An Anticancer Moiety for Human
Current Medicinal Chemistry Selenium-Rich Foods: a Promising Approach to Colorectal Cancer Prevention
Current Pharmaceutical Biotechnology Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Comprehensive Analysis of Key Proteins Involved in Radioresistance of Prostate Cancer by Integrating Protein-protein Interaction Networks
Current Bioinformatics Natural Product Gossypol and its Derivatives in Precision Cancer Medicine
Current Medicinal Chemistry